Hemo Organic Intrinsic Value
Hemo Organic (HEMORGANIC) median intrinsic value is ₹4.99 from 4 valuation models (range ₹5–₹6), vs current price ₹16.64 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Browse HEMORGANIC balance sheet details for revenue, profit, balance sheet and cash flow data.
HEMORGANIC Valuation Methods Summary — DCF, Graham Number & P/E
Hemo Organic intrinsic value across 4 models vs current price ₹16.64 — upside/downside and value range per method. Also explore HEMORGANIC share price charts to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹4.99 | ₹3.99 - ₹5.99 | -70.0% | EPS: ₹0.30, Sector P/E: 12x |
| Revenue Multiple Method | revenue | ₹6.00 | ₹5.40 - ₹6.60 | -63.9% | Revenue/Share: ₹7.50, P/S: 0.8x |
| PEG Ratio Method | growth | ₹4.99 | ₹4.49 - ₹5.49 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹4.99 | ₹4.49 - ₹5.49 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
HEMORGANIC Intrinsic Value vs Market Price — All Valuation Models
Hemo Organic fair value range ₹5–₹6 vs current market price ₹16.64 across 4 valuation models. For current market price and key ratios, visit Hemo Organic share price today.
HEMORGANIC Intrinsic Value Analysis — Undervalued or Overvalued?
Hemo Organic median intrinsic value ₹4.99, current price ₹16.64 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of HEMORGANIC?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Hemo Organic (HEMORGANIC) is ₹4.99 (median value). With the current market price of ₹16.64, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹4.99 to ₹6.00, indicating ₹4.99 - ₹6.00.
Is HEMORGANIC undervalued or overvalued?
Based on our multi-method analysis, Hemo Organic (HEMORGANIC) appears to be trading above calculated value by approximately 70.0%.
HEMORGANIC Financial Health — Key Ratios vs Industry Benchmarks
Hemo Organic financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.60x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
HEMORGANIC Cash Flow Quality — Operating & Free Cash Flow
Hemo Organic operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |